Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 4:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 381 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Diabetes Mellitus, Hyperglycemia, Hypoglycemia
Interventions
Self blood glucose monitoring and insulin administration, Standard care
Procedure
Lead sponsor
Atlanta VA Medical Center
Federal
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Decatur, Georgia
Conditions
Hypoxic-Ischemic Encephalopathy, Hypoglycemia, Neonatal Abstinence Syndrome
Interventions
nfant feeding solution
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 6 Months
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 2 Interventional Results available

G-Pen™ for Hypoglycemia Rescue in T1D Patients

NCT02423980
Conditions
Hypoglycemia
Interventions
Glucagon
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Walnut Creek, California
Conditions
Congenital Hyperinsulinism
Interventions
RZ358 Sequential Group Cohort 1, RZ358 Sequential Group Cohort 2, RZ358 Sequential Group Cohort 3, RZ358 Sequential Group Cohort 4
Drug
Lead sponsor
Rezolute
Other
Eligibility
2 Years to 45 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Fort Worth, Texas
Conditions
Hypoglycemia
Interventions
XOMA 358 single dose level A, XOMA 358 single dose level B, XOMA 358 single dose level C, XOMA 358 multiple dose level 1
Drug
Lead sponsor
XOMA (US) LLC
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
5
States / cities
Aurora, Colorado • Chicago, Illinois • Baltimore, Maryland + 2 more
Conditions
Diabetes
Interventions
Continuous Glucose Monitoring (CGM)
Device
Lead sponsor
DexCom, Inc.
Industry
Eligibility
2 Years and older
Enrollment
1,388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
25
States / cities
La Jolla, California • La Mesa, California • Sacramento, California + 21 more
Conditions
Type 1 Diabetes Mellitus, Hypoglycemia
Interventions
EnMPC (Ensemble Model Predictive Control) AP Controller, rMPC (Naïve Model Predictive Control) AP Controller
Device
Lead sponsor
Marc Breton
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Severe Hypoglycemia
Interventions
Proactive Care Management, MyHC-T2D education program
Other · Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Hyperglycemia, Vaccine Adverse Reaction
Interventions
None (not interventional)
Other
Lead sponsor
Levenson, David I., M.D.
Individual
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boca Raton, Florida
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase

NCT04028960
Conditions
Type1diabetes
Interventions
Regular insulin (Humulin-R), intranasal route, SipNose intranasal device
Drug · Device
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Neonatal Hypoglycemia
Interventions
Continuous Glucose Monitoring Device
Device
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
1 Minute to 2 Weeks
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Hershey, Pennsylvania
Not yet recruiting Not applicable Interventional

Continuous Glucose Monitoring in Metabolic Surgery

NCT07095972
Conditions
Obesity (Disorder)
Interventions
Abbot Freestyle Libre CGM
Device
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Conditions
Type 1 Diabetes Mellitus With Hypoglycemia
Interventions
VC-02 Combination Product
Combination Product
Lead sponsor
ViaCyte
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Duarte, California • Irvine, California • Sacramento, California + 4 more
Conditions
Diabetes Mellitus, Type I
Interventions
Not listed
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
10 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
5
States / cities
Stanford, California • Denver, Colorado • New Haven, Connecticut + 2 more
Conditions
Hypo-unawareness, Type 1 Diabetes Mellitus
Interventions
Medium chain triglycerides
Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Type 1 Diabetes, Hypoglycemia, Hyperglycaemia Due to Type 1 Diabetes Mellitus, Menstruation Disturbances
Interventions
Personalized modifications to treatment to address menstrual cycle effects on glycemia
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Critical Illness
Interventions
Freestyle Navigator
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Differing Levels of Hypoglycemia

NCT02445781
Conditions
Hypoglycemia
Interventions
Glucose clamp
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Terminated No phase listed Observational Accepts healthy volunteers

Continuous Glucose Monitoring in Neonatal Hyperinsulinism

NCT06363929
Conditions
Hyperinsulinism, Hypoglycemia Neonatal
Interventions
Dexcom G6 continuous glucose monitor
Device
Lead sponsor
MemorialCare Health System
Other
Eligibility
24 Hours to 3 Months
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Long Beach, California
Completed No phase listed Observational

Insulin Infusion in the Hospital Wards

NCT00412347
Conditions
Hyperglycemia
Interventions
Insulin Drip Therapy
Drug
Lead sponsor
Emory University
Other
Eligibility
19 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Hypoglycemia
Interventions
dasiglucagon, placebo, GlucaGen HypoKit
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
6 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Escondido, California • New Haven, Connecticut • Indianapolis, Indiana
Conditions
Postbariatric Hypoglycemia
Interventions
Mizagliflozin
Drug
Lead sponsor
Vogenx, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Palo Alto, California • Aurora, Colorado
Terminated Phase 1 Interventional Accepts healthy volunteers

Role of GLP-1 in Hyperinsulinemic Hypoglycemia Post-bariatric Surgery

NCT02550145
Conditions
Hypoglycemia
Interventions
Exendin (9-39), Placebo
Drug · Other
Lead sponsor
Tracey McLaughlin
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Stanford, California
Conditions
Diabetes Mellitus, Type 1
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
New Haven, Connecticut • Minneapolis, Minnesota